Table 2. Most frequently recognized peptides.
| Peptide a | Peptide Set b | WT or DR | DR position overlapped | HIV Protein | Individuals responding to peptide [n (%)] | Median magnitude of responses (range; SFC/106 cells) | Potentially restricting HLA c |
|---|---|---|---|---|---|---|---|
| NLLTQIGCT | a | WT | L90M | PR | 15 (31) | 230 (60–484) | B*18 |
| GRNLLTQIG | a | WT | L90M | PR | 14 (29) | 135 (56–290) | C*02 |
| RNLMTQIGC | a | DR | L90M | PR | 14 (29) | 170 (51–450) | A*11, C*04 |
| QHLLRWGLY | a | DR | T215Y | RT | 12 (24) | 115 (60–200) | C*02, C*15 |
| EELRQHLLRW | b | WT | L210W | RT | 12 (24) | 90 (70–164) | B*39 |
| KMIGGVGGFI | b | DR | I50V | PR | 11 (22) | 90 (51–162) | B*39 |
| ITLWQRPIV | b | DR | L10I | PR | 10 (20) | 169 (56–450) | A*33, C*02, C*16 |
| DTVIEEMNL | b | DR | L33I | PR | 10 (20) | 162 (60–380) | C*02 |
| IGRNLLTQI | a | WT | L90M | PR | 9 (18) | 123 (70–260) | A*26, A*80, B*42, C*17 |
| EKEGKISKI | b | WT | E44D | RT | 9 (18) | 87 (56–190) | A*02, A*80, B*38, B*47 |
| YQYVDDLYV | b | DR | M184V | RT | 9 (18) | 322 (58–1150) | A*01, A*02, B*47 |
| LRWGLYTPD | a | DR | T215Y | RT | 8 (16) | 99 (58–163) | A*02, A*11 |
| TVLIGPTPV | a | DR | V77I | PR | 8 (16) | 120 (82–200) | A*33, A*74, A*80, B*45, C*16, C*02 |
| DTIFEEMNL | b | DR | V32I, L33F | PR | 8 (16) | 94 (50–190) | A*33, A*74, A*80 |
| LVGPTPANI | b | DR | V82A | PR | 8 (16) | 87 (50–130) | A*02, A*80, B*39, B*42, B*47, C*17 |
| NTPVFAIKR | b | DR | K65R | RT | 8 (16) | 98 (67–160) | A*80, B*42, C*14 , C*17 |
| KKSVTVLDVGDAYFS | b | WT | K103N, V106M, V108I, Y115F, F116Y | RT | 8 (16) | 223 (51–930) | A*24, A*26 |
| NKSMTILDVGDAFYS | b | DR | K103N, V106M, V108I, Y115F, F116Y | RT | 8 (16) | 89 (52–119) | A*80, B*15, B*38, B*42, C*17 |
| KQNPDIVIY | b | WT | Y181C | RT | 8 (16) | 195 (50–523) | A*24, A*26, A*74, A*80, B*42, B*47, C*02, C*17 |
| KQNPDIVIC | b | DR | Y181C | RT | 8 (16) | 170 (60–532) | A*24, A*26, B*39, B*42, C*17 |
| NPDIVICQYM | b | DR | Y181C | RT | 8 (16) | 116 (60–200) | A*02, A*26, B*27 |
| YQYMDDLYV | b | WT | M184V | RT | 8 (16) | 292 (80–1050) | A*02, A*80, B*18 |
a A list of the 22 most frequently recognized peptides in the study cohort is shown (>15% of individuals responding). Positions associated with DR are shown in bold.
b According to peptide design rationale as explained in Methods.
c HLA alleles significantly more frequent in individuals responding to the peptide are shown (p<0.01, q<0.2, Mann-Whitney test). HLA molecules that have previously been experimentally linked to the corresponding epitope are shown in bold (Los Alamos HIV Immunology Database). HLA molecules predicted to bind the corresponding epitope using the ELF tool (Los Alamos HIV Immunology Database) are shown in italics.
PR, protease; RT, reverse transcriptase; SFC, spot forming cells.